7Boente MP,Chids,HosKins WJ.The roles of surgery in the managerment of ovarian cancer primary and interval cytoreductive surgery[J].Semin in Oncol,1998,25:326.
8Kuhn W,Rutke S,Spathe K,et al.Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in international Federation of Gynecology and Obstetrics StageⅢ ovarian carcinoma[J].Cancer,2001,92(12):2585.
9Emanuel F. Petricoin,Cloud P. Paweletz,Lance A. Liotta. Clinical Applications of Proteomics: Proteomic Pattern Diagnostics[J] 2002,Journal of Mammary Gland Biology and Neoplasia(4):433～440
3Hance KW, Anderson WF, Devesa SS, et al. Trends in in- flammatory breast carcinoma incidence and survival: the surveillance, epidemiology and end results program at na- tional cancer institute[J]. Jounal of the National Cancer lnst, 2005,97 (13) : 966.
7Liekweg A, Westfeld M, Braun M, et al.Pharrnaceutical care for patients with breast and ovarian cancer[J].Sup- port Care Cancer, 2012,20( 11 ) : 2 669.
8Cioffi P, Antonelli D, Belfiglio M, et al.The impact of a pharmacist as a member of healthcare team on facilitating evidenced-based prescribing of innovative drugs in an Ital- ian oncology department[J], Journal of Ontology Pharma- cy Practice , 2012 ,18 ( 2 ) :207.
9Avery AJ, Rodgers S, Cantrill JA, et al.A pharmacist-led information technology intervention for medication errors (PINCER) : a multicentre, cluster randomised, con- trolled trial and cost-effectiveness analysis[J]. Lancet, 2012,379(9 823):1 310.
